THERANOSTICS 2016* Uta Eberlein
University of Würzburg, , Germany
- This delegate is presenting an abstract at this event.
Presentations this author is a contributor to:
Patient dosimetry assessment with the somatostatin receptor antagonist 68Ga-labelled OPS202 in the first clinical study of gastroenteropancreatic neuroendocrine tumors (GEP-NET) (#67)
8:30 AM
Uta Eberlein
Conference Breakfast: Moderated Poster Walk - Neuroendocrine tumours
In-vitro dose calibration of the DNA damage assay for internal irradiation of blood lymphocytes with the PET nuclide 68Ga (#106)
8:30 AM
Uta Eberlein
Conference Breakfast: Moderated Poster Walk - Novel Theranostics
DNA damage assay in blood lymphocytes in peptide receptor radionuclide therapy (PRRT) patients with personalised high activities (#7)
11:45 AM
Uta Eberlein
Refining and Defining NET Targets (submitted abstracts)